FEES JESSICA 4
4 · Surface Oncology, Inc. · Filed Nov 27, 2020
Insider Transaction Report
Form 4
FEES JESSICA
See Remarks
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2020-11-25−173→ 13,905 totalExercise: $4.27Exp: 2029-03-01→ Common Stock (173 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2020-11-25−982→ 2,654 totalExercise: $5.41Exp: 2027-06-27→ Common Stock (982 underlying) - Exercise/Conversion
Common Stock
2020-11-25$5.41/sh+982$5,315→ 102,182 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-11-25−227→ 455 totalExercise: $4.14Exp: 2026-12-09→ Common Stock (227 underlying) - Exercise/Conversion
Common Stock
2020-11-25$4.27/sh+1$4→ 102,183 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-11-25−1→ 25,999 totalExercise: $4.27Exp: 2029-03-01→ Common Stock (1 underlying) - Exercise/Conversion
Common Stock
2020-11-25$4.14/sh+227$939→ 101,027 total - Exercise/Conversion
Common Stock
2020-11-25$4.27/sh+173$739→ 101,200 total
Footnotes (4)
- [F1]This option shall vest in 48 equal monthly installments after January 1, 2017.
- [F2]The stock option vests and becomes exercisable in 48 equal monthly installments after November 18, 2018.
- [F3]This option shall vest in 48 equal monthly installments after July 1, 2017.
- [F4]The stock option vests and becomes exercisable in 48 equal monthly installments after February 12, 2019.